
Clean Safety Profile


Buntanetap (previously known as ANVS401 or Posiphen) is our lead compound. It is a translational inhibitor of neurotoxic aggregating proteins (TINAPs). Different from monoclonal antibody therapies, buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins at once. Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases. Buntanetap is the only drug to attack multiple neurotoxic proteins simultaneously.
Chronic and acute brain insults lead to high levels of neurotoxic proteins, inflammation and neurodegeneration.
Attacking one neurotoxic protein results in minimal effect.
Buntanetap is the only drug to attack multiple neurotoxic proteins simultaneously.
Buntanetap inhibits the translation of neurotoxic proteins by increasing the binding of a special mRNA sequence that is preserved among neurotoxic aggregating proteins and its binding protein that keeps it from going to the ribosome and being translated. Details see: Cheng 2021
Buntanetap, thus, offers a transformative and superior mechanism to treat neurodegenerative disorders. It is being developed for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions.
Lowering the levels of neurotoxic proteins restores axonal transport to normal speed. In several studies, we have shown that buntanetap and ANVS405 improve all the functions that are negatively affected by disturbances of axonal transport. Our research consistently shows that by reducing APP, tau and αSYN levels, buntanetap treatment improves axonal transport and impedes the toxic cascade which leads to neurodegeneration, thereby improving or restoring the affected function.









Buntanetap, and where noted, buntanetap and/or ANVS405, reduced multiple neurotoxic proteins and therefore, rescued neuronal health and restored animals’ normal functions.
Lowered levels of neurotoxic proteins (ANIMAL):
Improved retrograde and anterograde axonal transport (ANIMAL):
Increased synaptic transmission in (ANIMAL):
Increased neurotransmitter release in (ANIMAL):
Increased levels of neurogenesis and BDNF in (ANIMAL):
Buntanetap and ANVS405 lowered inflammation in (MCI HUMANS and ANIMAL):
ANVS405 protected nerve cells in (ANIMAL):
In summary buntanetap improves or restores the affect function in seven different animal models:
In four models of memory and learning: AD mice [Teich at al. 2018]; Down syndrome mice [Chen et al. 2020]; stroke mice [Turcato et al 2018]; traumatic brain injury rats [Chesselet UCLA, submitted for publication]
In two models of movement disorder: PD mice [Kuo et al. 2019] and in FTD mice.
Finally, it protects the retina and eyesight in acute glaucoma rats.

